Pfizer reports phase 3 clinical trial results for Lyme disease vaccine candidate
Pfizer announced results from a phase 3 clinical trial of its Lyme disease vaccine candidate, showing more than 70 percent effectiveness at preventing the illness. The vaccine was developed in partnership with Valneva. This represents a significant development in Lyme disease prevention, as there is currently no approved vaccine for the disease in the United States.
8
Divergence score
2 outlets covered it, splitting into 2 framing camps across 2 bias groups.
2 camps
2 bias groups
The spectrum · how 2 outlets placed this story
LeftCenterRight
The Hill
Wall Street Journal
Supportive of action
Neutral
Dismissive
Critical
Alarmist
International angle
Widest split · the two outlets furthest apart, and who published first
Furthest apart on this story
The Hill
Pfizer's Lyme disease vaccine candidate shows promising results
positive medical breakthrough
Wall Street Journal
Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial - WSJ
clinical trial data report
First to report
- Wall Street Journalfirst
- The Hill+12.5 h
By each outlet's earliest publish time in this story. Feeds that index slowly can appear later than they printed.
How each outlet covered it
Lightly covered so far
Too few outlets to map a left-right split. Here is each take as it stands.
Sparse coverage · 2 outlets
“Pfizer's Lyme disease vaccine candidate shows promising results”
“Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial - WSJ”
3 tracked claims across 2 outlets
Fact ledger
All3Claimed1Corroborated2
1/2
Claimed
Valneva is a co-developer of the Lyme disease vaccine candidate.
Corroborated
Disputed
2 more tracked claimsSign up free to see the full ledger